scholarly journals Cancer/Testis Antigen CAGE Exerts Negative Regulation on p53 Expression through HDAC2 and Confers Resistance to Anti-cancer Drugs

2010 ◽  
Vol 285 (34) ◽  
pp. 25957-25968 ◽  
Author(s):  
Youngmi Kim ◽  
Hyunmi Park ◽  
Deokbum Park ◽  
Yun-Sil Lee ◽  
Jongseon Choe ◽  
...  
Keyword(s):  
Negative Regulation ◽  
Cancer Testis Antigen ◽  
Cancer Drugs ◽  
P53 Expression ◽  
Anti Cancer ◽  
Cancer Testis

scholarly journals Role of HDAC3-miRNA-CAGE Network in Anti-Cancer Drug-Resistance

2018 ◽  
Vol 20 (1) ◽  
pp. 51 ◽  
Author(s):  
Yoojung Kwon ◽  
Youngmi Kim ◽  
Hyun Jung ◽  
Dooil Jeoung
Keyword(s):  
Molecular Networks ◽  
Cancer Drug ◽  
Cancer Drugs ◽  
Angiogenic Potential ◽  
Histone Deacetylase 3 ◽  
Cancer Drug Resistance ◽  
Tumorigenic Potential ◽  
Anti Cancer ◽  
Cancer Testis

Histone modification is associated with resistance to anti-cancer drugs. Epigenetic modifications of histones can regulate resistance to anti-cancer drugs. It has been reported that histone deacetylase 3 (HDAC3) regulates responses to anti-cancer drugs, angiogenic potential, and tumorigenic potential of cancer cells in association with cancer-associated genes (CAGE), and in particular, a cancer/testis antigen gene. In this paper, we report the roles of microRNAs that regulate the expression of HDAC3 and CAGE involved in resistance to anti-cancer drugs and associated mechanisms. In this review, roles of HDAC3-miRNAs-CAGE molecular networks in resistance to anti-cancer drugs, and the relevance of HDAC3 as a target for developing anti-cancer drugs are discussed.

Abstract LB-123: Analyses of anti-cancer testis antigen antibodies in glioma patients treated with Delta-24 oncolytic adenovirus

2012 ◽  
Author(s):  
Juan Fueyo ◽  
Charles Conrad ◽  
Candelaria Gomez-Manzano ◽  
Amy Heimberger ◽  
Luis Vence ◽  
...  
Keyword(s):  
Oncolytic Adenovirus ◽  
Cancer Testis Antigen ◽  
Anti Cancer ◽  
Cancer Testis

scholarly journals Cancer testis antigen PRAME: An anti‐cancer target with immunomodulatory potential

2021 ◽  
Author(s):  
Adviti Naik ◽  
Remy Thomas ◽  
Ghaneya Al‐Khadairi ◽  
Rim Bacha ◽  
Wouter Hendrickx ◽  
...  
Keyword(s):  
Cancer Testis Antigen ◽  
Anti Cancer ◽  
Immunomodulatory Potential ◽  
Cancer Testis

A Case of Malignant Melanoma Treated with a Combination of Anti-Cancer Drugs and Biological Response Modifiers.

1993 ◽  
Vol 55 (1) ◽  
pp. 43-46
Author(s):  
Jun YOSHIDA ◽  
Juichiro NAKAYAMA ◽  
Nobuyuki SHIMIZU ◽  
Shonosuke NAGAE ◽  
Yoshiaki HORI
Keyword(s):  
Malignant Melanoma ◽  
Biological Response ◽  
Biological Response Modifiers ◽  
Cancer Drugs ◽  
Anti Cancer

Current Scenario in Structure and Ligand-Based Drug Design on Anti-colon Cancer Drugs

2019 ◽  
Vol 24 (32) ◽  
pp. 3829-3841 ◽  
Author(s):  
Lakshmanan Loganathan ◽  
Karthikeyan Muthusamy
Keyword(s):  
Drug Discovery ◽  
Drug Design ◽  
Anticancer Agent ◽  
Computational Power ◽  
Cancer Drugs ◽  
Recent Advances ◽  
Anti Cancer ◽  
Drug Designing ◽  
Current Scenario ◽  
Molecular Modeling Studies

Worldwide, colorectal cancer takes up the third position in commonly detected cancer and fourth in cancer mortality. Recent progress in molecular modeling studies has led to significant success in drug discovery using structure and ligand-based methods. This study highlights aspects of the anticancer drug design. The structure and ligand-based drug design are discussed to investigate the molecular and quantum mechanics in anti-cancer drugs. Recent advances in anticancer agent identification driven by structural and molecular insights are presented. As a result, the recent advances in the field and the current scenario in drug designing of cancer drugs are discussed. This review provides information on how cancer drugs were formulated and identified using computational power by the drug discovery society.

Sign in / Sign up

Export Citation Format

Share Document